We work at the convergence of science, medicine, and engineering to reinvent the process of drug discovery and treatment.
The Harvard Program in Therapeutic Science (HiTS) is an academic research and education program that advances the fundamental science underlying human diseases and drug discovery in order to improve patient care.
The program’s faculty, trainees, and staff study disease using innovative approaches that fuse laboratory investigation, clinical research and computer science to accelerate the invention of life-saving medicines and the precision diagnostics needed to optimally treat individual patients. Our program brings together two approaches: Systems Pharmacology provides a powerful means to study the changes that promote disease and the ways in which therapeutic drugs function at a molecular level. Regulatory science focuses on the evaluation of drugs in clinical trials and on balancing the benefits and risks of new medicines.
Learn about our components:
Explore HiTS Research
News, Events, & Updates
HiTS Social Lunch
“Trivia and Lunch”
September 13, 2-1:30pm | ARM108
Regulatory Science Forum
“An Inflection Point for High-Quality Diagnostic Tests in Oncology”
Dr. Brian Alexander, CEO of Foundation Medicine
September 12, 12:00pm ET
Twitter @HiTSatHarvard
This will be fun! We'll discuss what *really* happens when biotechs interact with the FDA...
Geared toward students & academic folks, but open to all. Free (registration req'd).
There are many @lmardmwg members offering data-related training. Check out these data management seminars across the data lifecycle. See how far you and your research team can expand your data management toolbox! https://datamanagement.hms.harvard.edu/training-events/rdmwg-calendar
What's your #OpenScience story?
@WHOSTP declared 2023 the Year of Open Science. To celebrate @HMSCountway wants to share your Open Science story during #OpenAccessWeek!
Submit your story here ➡️ https://hms.az1.qualtrics.com/jfe/form/SV_82MkDRhqjp33pK6
Dr. Santagata (@SantagataLab) et al. @harvardmed Pre-Cancer Atlases of Cutaneous & Hematologic Origin #HTAN Center are constructing a multidimensional atlas of genetic and epigenetic events that promote #melanoma #metastasis. https://humantumoratlas.org/hta7 #CancerMoonshot
A trial co-led by #MassGeneral physician Priscilla Brastianos, MD, was covered by @theNCI. In the trial, the drugs vemurafenib (Zelboraf) and cobimetinib (Cotellic) used together were found to substantially shrink brain tumors in 15 of the 16 participants.